AbbVie CEO sees hep C market-share grab; FDA deems Roche PDL1 drug a breakthrough; Merck KGaA takes back Russian drug rights;

> AbbVie ($ABBV) expects its hepatitis C drug sales to top $3 billion this year, with CEO Richard Gonzalez predicting Viekira Pak can grab a "meaningful share" of the U.S. market despite competition from Gilead Sciences ($GILD). Report

> The FDA conferred its "breakthrough" designation on Roche's ($RHHBY) anti-PDL1 drug as a treatment for lung cancer; the field is heating up as Merck ($MRK) and Bristol-Myers Squibb ($BMY) vie to be the first with an approved NSCLC immunotherapy. Release

> Keen on emerging markets growth, Merck KGaA took back Russian marketing rights to its diabetes and thyroid franchises from its partner Takeda. Release

> An Arizona court said it would allow a woman with lupus to sue Scottsdale-based Medicis Pharmaceuticals, now a Valeant ($VRX) unit, over alleged risks of its acne drug Solodyn. Report

> The pharma market in France will grow hardly at all over the next several years, GlobalData says, with sales there hitting $48.2 billion by 2020. Report

And Finally... Just how prevalent is "non-personal promotion" in pharma marketing these days? Report

Suggested Articles

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.

Merck’s Keytruda is battling Bristol Myers' Opdivo in adjuvant melanoma, and it just racked up trial results that will help it even the playing field.

While the failure might be a missed chance at revenue, it shouldn’t hurt Ibrance’s ability to rack up sales in the metastatic setting, one exec says.